 HOUSTON, Dec. 11, 2020 GLOBE NEWSWIRE -- Salarius Pharmaceuticals, Inc. Nasdaq: SLRX, a clinical-stage biopharmaceutical company developing potential new medicines for patients with pediatric cancers, solid tumors, and other cancers, today announced that it has entered into agreements with several institutional and accredited investors the Exercising Holders to exercise certain outstanding warrants to purchase an aggregate of up to 3,964,065 shares of common stock raising gross proceeds of approximately 3.5 million. These warrants were previously issued in Salarius public offering which closed in February 2020. 